Key facts
- This page summarizes William R. Sellers's Form 4 filing for 2seventy bio, Inc. (TSVT).
- 5 reported transactions and 3 derivative rows are listed below.
- Accepted by SEC: 16 Nov 2021, 05:48.
William R. Sellers - 11 Nov 2021 Form 4 Insider Report for 2seventy bio, Inc. (TSVT)
- Reporting relationship
- Director
- Issuer ticker
- TSVT
- Reported as of
- 11 Nov 2021
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 16 Nov 2021, 05:48:03 UTC
- Prior SEC filing
- 18 Oct 2021
- Source filing
- View source filing
- Reporting owner signature
- /s/ Teresa Jurgensen, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
William R. Sellers filed Form 4 for 2seventy bio, Inc. (TSVT) on 16 Nov 2021.
Change
- Previous filing in this sequence was filed on 18 Oct 2021.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
TSVT
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +219
- Change %
- Price
- $0.000000
- Shares after
- 219
- Date
- 11 Nov 2021
- Ownership
- Direct
- Footnotes
- F1, F2, F3
TSVT
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +2,002
- Change %
- +167%
- Price
- $0.000000
- Shares after
- 3,202
- Date
- 11 Nov 2021
- Ownership
- Direct
- Footnotes
- F2, F3, F4, F5
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
TSVT
transaction
Derivative
Stock Option (right to buy)
Award
- Transaction value
- $0
- Shares
- +2,625
- Change %
- Price
- $0.000000
- Shares after
- 2,625
- Date
- 11 Nov 2021
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 2,625
- Exercise price
- $163.24
- Footnotes
- F6, F7
TSVT
transaction
Derivative
Stock Option (right to buy)
Award
- Transaction value
- $0
- Shares
- +984
- Change %
- Price
- $0.000000
- Shares after
- 984
- Date
- 11 Nov 2021
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 984
- Exercise price
- $99.53
- Footnotes
- F6, F8
TSVT
transaction
Derivative
Stock Option (right to buy)
Award
- Transaction value
- $0
- Shares
- +3,219
- Change %
- Price
- $0.000000
- Shares after
- 3,219
- Date
- 11 Nov 2021
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 3,219
- Exercise price
- $50.98
- Footnotes
- F6, F9
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 9 footnotes
Footnote F1
In connection with the separation (the "Separation") of seventy bio, Inc. ("2seventy") from bluebird bio, Inc. ("bluebird"), the reporting person received restricted stock units, each representing the right to receive a share of 2seventy's common stock, as a result of the adjustment of existing bluebird restricted stock units prior to the Separation (see footnotes 2 and 3). This restricted stock unit award vests ratably over three years in annual installments commencing on September 25, 2019.
Footnote F2
bluebird equity awards granted prior to January 1, 2021 were converted into equity awards of both bluebird and 2seventy. The number of shares underlying the converted bluebird equity awards was determined by multiplying the number of shares underlying the existing bluebird equity award by a fraction, the numerator of which is the volume-weighted average trading price of bluebird common stock (trading "regular way") on the five trading days immediately prior to the distribution date (the "bluebird Pre-Distribution VWAP"), the denominator of which is the sum of (1) the volume-weighted average trading price of 2seventy common stock (trading "regular way") on the five trading days immediately following the distribution date (the "2seventy VWAP") multiplied by the distribution ratio and (2) the volume-weighted average trading price of bluebird common stock (trading "regular way") on the five trading days immediately following the distribution date (the "bluebird Post-Distribution VWAP").
Footnote F3
The number of shares underlying the converted 2seventy equity awards was determined by multiplying the number of shares underlying the existing bluebird equity awards by a fraction, the numerator of which is the bluebird Pre-Distribution VWAP and the denominator of which is the sum of (1) the 2seventy VWAP multiplied by the distribution ratio and (2) the quotient obtained by dividing the bluebird Post-Distribution VWAP by the distribution ratio. bluebird equity awards granted on or after January 1, 2021, such equity awards were converted into 2seventy equity awards. The number of shares of 2seventy common stock underlying such converted equity awards is equal to the number of shares of bluebird common stock subject to the equity award immediately prior to the distribution multiplied by a fraction, the numerator of which is the bluebird Pre-Distribution VWAP and the denominator of which is the 2seventy VWAP.
Footnote F4
In connection with the Separation, the reporting person received restricted stock units, each representing the right to receive a share of 2seventy's common stock, as a result of the adjustment of existing bluebird restricted stock units prior to the Separation (see footnotes 2 and 3). This restricted stock unit award vests 100% on the earlier of June 15, 2022 or the date of the next annual meeting of stockholders.
Footnote F5
Includes 981 shares of 2seventy's common stock received in a pro rata distribution by bluebird as a result of the Separation.
Footnote F6
Represents options to purchase shares of 2seventy's common stock granted to the reporting person in connection with the Separation (see footnotes 2 and 3).
Footnote F7
This option vests ratably over three years in annual installments commencing on September 25, 2019 (see footnotes 2 and 3).
Footnote F8
This option is fully vested and exercisable as of the date hereof (see footnotes 2 and 3).
Footnote F9
This option vests 100% on the earlier of June 15, 2022 or the date of the next annual meeting of stockholders (see footnotes 2 and 3).
SEC remarks
**Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.